About
About START

Welcome to the START Center for Cancer Research. We are a global leader in cancer research, dedicated to the relentless pursuit of hope for patients and their families.

About

Company

Hope Hub

Leadership

Principal Investigators

Careers

Contact

Our Services

Preclinical

Early Phase
Who We Serve
Who We Serve

We believe that every patient should have the opportunity to access clinical trials, regardless of where they receive their cancer treatment.

Patients & Family

Patients

Explore Clinical Trials

About Clinical Trials

Patient Stories

Referring Physicians

Referring Physicians

Hospitals & Oncology Practices

Hospitals & Oncology Practices

Pharma

Pharma
START Locations
START Research Centers

100,000+ square feet of world-class research facilities

United States Locations

START - San Antonio

START - Midwest

START - Mountain Region

START - Carolinas

START - New York City (Coming Soon)

START - Dallas Fort Worth (Coming Soon)

START - New Jersey (Coming Soon)

START - Los Angeles (Coming Soon)

Europe Locations

START - Madrid - CIOCC

START - Madrid - FJD

START - Barcelona

START - Rioja

START - Lisbon

START - Dublin
Resources
Resources

Stay up to date with everything at START, from blog insights and press and newsroom updates to expert-led webinars and much more.

Resources

Blog

Events

Newsroom

Press

Publications

Webinars

Featured Resources

Newsroom

START Launches Hope Hub to Connect Patients, Physicians, and Advocacy Groups to Community-Based Cancer Trials

Blog

Sourcing Better PDX Models with a Streamlined “Clinic-to-Bench” Pipeline
Find a Trial

Publication

A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors

A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors Read More »

A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors

Leave a Comment / Publication / Joel E

A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors Read More »

A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (PODIUM-101)

Leave a Comment / Publication / Joel E

A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (PODIUM-101) Read More »

First-in-human study with preclinical data of Bcl-2/Bcl-XL inhibitor Pelcitoclax in locally advanced or metastatic solid tumors

Leave a Comment / Publication / Joel E

First-in-human study with preclinical data of Bcl-2/Bcl-XL inhibitor Pelcitoclax in locally advanced or metastatic solid tumors Read More »

Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study

Leave a Comment / Publication / Joel E

Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study Read More »

Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)

Leave a Comment / Publication / Joel E

Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts) Read More »

A First-in-Human Phase 1 Study of ABBV-525, a Small-Molecule MALT1 Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Leave a Comment / Publication / Joel E

A First-in-Human Phase 1 Study of ABBV-525, a Small-Molecule MALT1 Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Read More »

Histology-agnostic drugs: A paradigm shift – A narrative review

Leave a Comment / Publication / Joel E

Histology-agnostic drugs: A paradigm shift – A narrative review Read More »

Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)

Leave a Comment / Publication / Joel E

Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma) Read More »

Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes

Leave a Comment / Publication / Joel E

Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes Read More »

Partnership

Quis volutpat scelerisque quis massa in dolor nunc lectus cursus.

Varius nec, elit turpis amet, proin ut sed nec donec auctor dolor arcu, sollicitudin.

Enim nulla elementum sodales dapibus orci, sed quam mattis aliquam dui penatibus aliquet feugiat nisl laoreet placerat pellentesque duis semper pellentesque tempor placerat nam parturient magna volutpat auctor mattis imperdiet sapien ut tortor id amet tempor tortor, augue facilisi mi.

About START

About

Our Services

Who We Serve

Patients & Family

Referring Physicians

Hospitals & Oncology Practices

Pharma

Resources

Resources

Featured Resources

START Launches Hope Hub to Connect Patients, Physicians, and Advocacy Groups to Community-Based Cancer Trials

Sourcing Better PDX Models with a Streamlined “Clinic-to-Bench” Pipeline

Publication

Partnership

Quis volutpat scelerisque quis massa in dolor nunc lectus cursus.